LivaNova Plc - Company Profile
Powered by 
All the data and insights you need on LivaNova Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date LivaNova Plc Strategy Report
- Understand LivaNova Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
LivaNova PLC (LivaNova) is a medical technology company that offers medical devices for cardiac surgery and neuromodulation. The company’s neuromodulation products provide vagus nerve stimulation therapy system, an implantable device for the people affected by treatment-resistant epilepsy, depression, heart failure and other chronic disorders. Its cardiovascular surgery products include oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories; systems for the autotransfusion and autologous blood washing, perfusion charting system, among others. The company offers its solutions to patients, healthcare professionals and healthcare systems. LivaNova is headquartered in London, Greater London, the UK.
Headquarters
United Kingdom
Address
20 Eastbourne Terrace, London, England, W26LG
Website
www.livanova.com/en-us
Telephone
44 20 33250662
No of Employees
2,900
Industry
Medical Equipment
Ticker Symbol & Exchange
LIVN (NASD)
Revenue (2023)
$1.2B
12.9%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
120.3%
(2023 vs 2022)
Market Cap*
$2.8B
Net Profit Margin (2023)
XYZ
118.0%
(2023 vs 2022)
* As of and is in US$
LivaNova Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oxygenators | VNS Therapy |
| Extracorporeal Blood Circulation Systems | VITARIA |
| Heart Lung Machines | Pulse |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In March, the company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz Heart-Lung Machine (HLM). |
| 2023 | New Products/Services | In February, the company launched SenTiva DUO, an implantable pulse generator. |
| 2022 | Regulatory Approval | In November, the company received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S. Food and Drug Administration (FDA) for LifeSPARC. |
Competitor Comparison
| Key Parameters | LivaNova Plc | Abbott Laboratories | Medtronic Plc | Edwards Lifesciences Corp | Haemonetics Corp |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | Ireland | United States of America | United States of America |
| City | London | Abbott Park | Dublin | Irvine | Boston |
| State/Province | England | Illinois | - | California | Massachusetts |
| No. of Employees | 2,900 | 114,000 | 95,000 | 19,800 | 3,034 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William Kozy | Chairman | Executive Board | 2018 | 71 |
| Vladimir A. Makatsaria | Chief Executive Officer; Director | Executive Board | 2024 | - |
| Alex Shvartsburg | Chief Financial Officer | Senior Management | 2021 | 53 |
| Trui Hebbelinck | Chief Human Resources Officer | Senior Management | 2019 | 51 |
| Michael Hutchinson | Secretary; Senior Vice President; Chief Legal Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward